Literature DB >> 8900906

Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease.

R J Schlemper1, S D van der Werf, I Biemond, C B Lamers.   

Abstract

OBJECTIVE: To explore the state of the gastric mucosa in individuals with and without peptic ulcer disease from populations with contrasting peptic ulcer risks.
DESIGN: Pepsinogen A, pepsinogen C, gastrin and Helicobacter pylori antibodies are serological markers of gastritis. A decreasing pepsinogen A-C ratio and pepsinogen A level are known to reflect an increasing severity of corpus atrophy, whereas gastrin levels decrease with an increasing severity of antral atrophy when corpus atrophy is present. Helicobacter pylori-positive men, with and without a peptic ulcer history, were the focus of the study.
METHODS: In 190 Japanese and 425 Dutch male employees, of similar age (mean age 49 years) and level of occupation, fasting serum samples were analysed in the same laboratory for IgG antibodies to H. pylori, pepsinogen A, pepsinogen C and gastrin. Any history of ulcer disease was verified through case notes.
RESULTS: The H. pylori seropositivity rate was higher in the Japanese men (72%) than in the Dutch (33%). There were 23 (12%) Japanese and 18 (4%) Dutch men with a verified duodenal ulcer history, and 14 (7%) Japanese and two (0.5%) Dutch men with a verified gastric ulcer history. H. pylori-positive men with a duodenal ulcer history differed from the H. pylori-positive men without an ulcer history in that they had a significantly higher mean pepsinogen A level (64 and 51 micrograms/l in Japanese men and 71 and 57 micrograms/l in Dutch men) and also a higher mean pepsinogen A-C ratio, whereas pepsinogen C and gastrin levels did not differ. In H. pylori-positive gastric ulcer patients the mean gastrin level was significantly lower than in H. pylori-positive men without ulcer disease (17 and 37 pmol/l in Japanese men), whereas pepsinogen levels were similar.
CONCLUSION: This study suggests that in H. pylori-positive duodenal ulcer patients there is less mucosal atrophy of the corpus and in H. pylori-positive gastric ulcer patients more atrophy of the antrum than in H. pylori-positive individuals without peptic ulcer disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900906     DOI: 10.1097/00042737-199601000-00007

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

Review 2.  Helicobacter pylori in First Nations and recent immigrant populations in Canada.

Authors:  Nicola Jones; Naoki Chiba; Carlo Fallone; Alan Thompson; Richard Hunt; Kevan Jacobson; Karen Goodman
Journal:  Can J Gastroenterol       Date:  2012-02       Impact factor: 3.522

Review 3.  Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection.

Authors:  Qian Ren; Xiang Yan; YongNing Zhou; Wei Xin Li
Journal:  Cochrane Database Syst Rev       Date:  2016-02-07

4.  Helicobacter pylori virulence factors in duodenal ulceration: A primary cause or a secondary infection causing chronicity.

Authors:  Frank I Tovey; Michael Hobsley; John Holton
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

5.  Influence of H pylori on plasma ghrelin in patients without atrophic gastritis.

Authors:  Mehmet Cindoruk; Ilhan Yetkin; Serpil Muge Deger; Tarkan Karakan; Erdal Kan; Selahattin Unal
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

6.  Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population.

Authors:  Abbas Zoalfaghari; Najmeh Aletaha; Nader Roushan; Reza Taslimi; Hossein Foroutan; Bita Faridnia
Journal:  Med J Islam Repub Iran       Date:  2014-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.